← Back to Clinical Trials
Recruiting NCT05819346

NCT05819346 Digital Lifestyle Intervention for Lung Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05819346
Status Recruiting
Phase
Sponsor Kai-Uwe Schmitt, PhD, MEng, ICID
Condition Non-Small Cell Lung Cancer (NSCLC)
Study Type INTERVENTIONAL
Enrollment 88 participants
Start Date 2023-08-01
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Lifestyle

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 88 participants in total. It began in 2023-08-01 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to assess the efficacy of a digital lifestyle intervention in non-small cell lung cancer (NSCLC) survivors on health-related quality of life (HRQoL) over three months.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of non-small cell lung cancer (NSCLC) * Estimated life expectancy of ≥ six months (judged by local investigators/responsible health professionals) * Undergoing inpatient or outpatient rehabilitation OR completion of planned surgery, chemotherapy, or radiation therapy for NSCLC within the past 24 weeks * Knowledge of German to understand study material and assessments * Access to a cell phone or tablet * Written informed consent Exclusion Criteria: * Inability to provide informed consent * Inability to participate in the intervention because of physical, cognitive, or safety reasons (judged by local investigators/responsible health professionals)

Contact & Investigator

Central Contact

Anja Frei, PhD

✉ anja.frei@uzh.ch

📞 +41 44 634 43 60

Principal Investigator

Anja Frei, PhD

PRINCIPAL INVESTIGATOR

University of Zurich

Frequently Asked Questions

Who can join the NCT05819346 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05819346 currently recruiting?

Yes, NCT05819346 is actively recruiting participants. Contact the research team at anja.frei@uzh.ch for enrollment information.

Where is the NCT05819346 trial being conducted?

This trial is being conducted at Barmelweid, Switzerland, Davos, Switzerland, Heiligenschwendi, Switzerland, Wald, Switzerland.

Who is sponsoring the NCT05819346 clinical trial?

NCT05819346 is sponsored by Kai-Uwe Schmitt, PhD, MEng, ICID. The principal investigator is Anja Frei, PhD at University of Zurich. The trial plans to enroll 88 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology